Sobi’s olezarsen (TRYNGOLZA) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending its use in adults with severe hypertriglyceridaemia (sHTG) and fasting triglyceride levels of at least 880 mg/dL (10 mmol/L). The recommendation, which covers use alongside diet and other lipid-lowering therapies, is based on […]
The post Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia appeared first on Pharmafile.